Humanin

Humanin is a small peptide belonging to the class of mitochondrial-derived peptides (MDPs), bioactive molecules encoded by short open reading frames within the mitochondrial genome rather than the nuclear DNA that specifies most proteins. It is a 24-amino-acid peptide in its originally described form and was the first MDP to be identified, discovered in 2001 in the surviving neurons of a patient with Alzheimer's disease during a search for factors that protect brain cells from amyloid-beta toxicity ^[5]. Its unusual origin, transcribed from the same mitochondrial region as the 16S ribosomal RNA gene, made it a founding example of the idea that mitochondria act as signaling hubs that secrete their own hormones, sometimes called mitokines ^[4][6].

Biologically, humanin is both neuroprotective and cytoprotective. It inhibits apoptosis and buffers cells against oxidative stress, endoplasmic reticulum stress, and inflammatory insults, and these actions have been documented across neuronal, cardiovascular, and metabolic systems ^[5]. Research analogues such as the potent derivative HNG are widely used to probe its effects in animals ^[4]. Circulating humanin is measurable in human blood, and its levels generally decline with age in multiple species, although paradoxically they can rise in the very old as part of a mitochondrial stress response ^[4][6].

Across the literature, humanin has been studied for a broad set of conditions tied to mitochondrial dysfunction and aging: Alzheimer's disease and cognition, type 2 diabetes and insulin resistance, atherosclerosis and myocardial injury, and overall lifespan and healthspan ^[1][2][4]. It is notably linked to human longevity, with elevated circulating levels observed in the offspring of centenarians, who are themselves more likely to reach exceptional age ^[4]. Humanin is not an approved drug; it and its analogues are investigational peptides used in research.

Humanin is a mitochondrial-derived peptide studied largely in preclinical and early research settings; human safety data are limited, and considerations are inferred from its biology rather than controlled trials. No serious toxicity has been characterized, but effective dose, long-term effects, and injection-related risks in humans are not established. It should be treated as an experimental research peptide.

Humanin was discovered in 2001 by researchers searching for survival factors in the surviving neurons of a brain affected by Alzheimer's disease, and it was named for its apparent ability to keep neurons alive. It was one of the first peptides found to be encoded not in the nuclear genome but within the mitochondrial 16S ribosomal RNA gene, helping to establish the concept of mitochondrial-derived peptides. Subsequent work by groups including those of Pinchas Cohen and Nir Barzilai linked circulating humanin to insulin sensitivity, cardioprotection, and human longevity. It remains an actively studied model molecule in the biology of aging and neurodegeneration.

Humanin is regarded as a landmark discovery in mitochondrial biology, admired for overturning the assumption that the mitochondrial genome encodes only the machinery of respiration. It draws sustained research interest because its levels track with biological aging and were reported to be elevated in the offspring of centenarians, a model of successful aging. Its broad cytoprotective profile, spanning neurons, the heart, and metabolic tissues, makes it a compelling subject for age-related decline. In honest appraisal, most evidence comes from cell and animal models or from correlational human studies, and humanin has not been developed into an approved therapy.